Trials & Filings

Allegro Begins Vitreomacular Traction Trial

Tests Integrin Peptide Therapy in VMT

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Allegro Ophthalmics has begun a Phase II study of ALG-1001 in patients with vitreomacular traction (VMT). ALG-1001 is a first-in-class Integrin Peptide Therapy targeting integrins, which play a key role in cell signaling and regulating cellular shape, motility, and the cell cycle. The study is a placebo-controlled, randomized, double-masked, dose-ranging trial to evaluate the safety and efficacy of intravitreal injections of ALG-1001 in patients with VMT. Patients are currently being enrolled a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters